<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03239015</url>
  </required_header>
  <id_info>
    <org_study_id>Long March Pathway</org_study_id>
    <nct_id>NCT03239015</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event</brief_title>
  <official_title>Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event (Long March Pathway)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baodong Qin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Changzheng Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is intended to evaluate efficacy and safety of targeted precision therapy in&#xD;
      patients with refractory tumor, including rare tumor without standard recommended treatment&#xD;
      and common tumor after multiple line of therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The individuals recruited in the present study are with solid tumor, mainly including two&#xD;
      parts: first, rare tumor without standard recommended treatment such as atypical fibrous&#xD;
      histiocytoma; second, common tumor after multiple line of therapy such as lung cancer,&#xD;
      gastric cancer, colorectal cancer, etc. All patients have no any standard therapy based on&#xD;
      NCCN guideline when recruiting. Next-generation sequence was used to detect druggable&#xD;
      molecular event including gene mutation, gene fusion, amplification, etc. Then patients with&#xD;
      molecular events were treated with corresponding targeted drug and followed-up, and not&#xD;
      limited tumor type. The efficacy and safety of targeted drug were evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>Evaluation of tumor burden based on RECIST criteria through study completion, an average of 2 months</time_frame>
    <description>Proportion of patients with reduction in tumor burden of a predefined amount, including complete remission and partial remission</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progress Free Survival</measure>
    <time_frame>Evaluation of tumor burden based on RECIST criteria until first documented progress through study completion, an average of 2 months</time_frame>
    <description>Time from treatment beginning until disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From date of treatment beginning until the date of death from any cause, through study completion, an average of 1 months</time_frame>
    <description>Time from treatment beginning until death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Effect</measure>
    <time_frame>Through study completion, an average of 1 months</time_frame>
    <description>Incidence of Treatment-related adverse Events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Rare Tumor</condition>
  <condition>Refractory Tumor</condition>
  <arm_group>
    <arm_group_label>Targeted Drug Therapy Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All recruited patients with druggable molecular event will be treated with corresponding targeted drug including Gefitinib/Erlotinib/Afatinib, Trastuzumab, Oxazolidine, Olaparib, Everolimus, Cabozantinib, Vemurafenib/Dabrafenib, and Palbociclib.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefitinib</intervention_name>
    <description>Gefitinib is an FDA/CFDA approved targeted drugs used for EGFR mutation based on NGS results.</description>
    <arm_group_label>Targeted Drug Therapy Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>Erlotinib is an FDA/CFDA approved targeted drugs used for EGFR mutation based on NGS results.</description>
    <arm_group_label>Targeted Drug Therapy Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Afatinib</intervention_name>
    <description>Afatinib is an FDA/CFDA approved targeted drugs used for EGFR mutation based on NGS results.</description>
    <arm_group_label>Targeted Drug Therapy Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Trastuzumab is an FDA/CFDA approved targeted drugs used for Her2 amplification based on NGS results.</description>
    <arm_group_label>Targeted Drug Therapy Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxazolidine</intervention_name>
    <description>Oxazolidine is an FDA/CFDA approved targeted drugs used for ALK or ROS-1 or MET fusion based on NGS results.</description>
    <arm_group_label>Targeted Drug Therapy Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olaparib</intervention_name>
    <description>Olaparib is an FDA/CFDA approved targeted drugs used for BRCA1/2 mutation based on NGS results.</description>
    <arm_group_label>Targeted Drug Therapy Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Everolimus is an FDA/CFDA approved targeted drugs used for mTOR or PI3KCA mutation based on NGS results.</description>
    <arm_group_label>Targeted Drug Therapy Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabozantinib</intervention_name>
    <description>Cabozantinib is an FDA/CFDA approved targeted drugs used for RET mutation based on NGS results.</description>
    <arm_group_label>Targeted Drug Therapy Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vemurafenib</intervention_name>
    <description>Vemurafenib is an FDA/CFDA approved targeted drugs used for BRAF mutation based on NGS results.</description>
    <arm_group_label>Targeted Drug Therapy Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabrafenib</intervention_name>
    <description>Dabrafenib is an FDA/CFDA approved targeted drugs used for BRAF mutation based on NGS results.</description>
    <arm_group_label>Targeted Drug Therapy Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib</intervention_name>
    <description>Palbociclib is an FDA/CFDA approved targeted drugs used for CDK4/6 mutation or amplification based on NGS results.</description>
    <arm_group_label>Targeted Drug Therapy Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Malignant solid tumors diagnosed histologically;&#xD;
&#xD;
          -  Common solid tumor patients have no any standard choice after multiple line of&#xD;
             therapy; Rare solid tumor did not have any standard recommended treatment;&#xD;
&#xD;
          -  Expected survival ≥ 1 month;&#xD;
&#xD;
          -  ECOG / PS score: 0-2, and the main organ function to meet the following criteria: HB ≥&#xD;
             90g / L, ANC ≥ 1.5 × 109 / L, PLT ≥ 80 × 109 / L,BIL &lt;1.5 times the upper limit of&#xD;
             normal (ULN); Liver ALT and AST &lt;2.5 × ULN and if liver metastases, ALT and AST &lt;5 ×&#xD;
             ULN; Serum Cr ≤ 1 × ULN, endogenous creatinine clearance ≥50ml/min&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient still has standard treatment therapy based on NCCN guidance;&#xD;
&#xD;
          -  Patient can not comply with research program requirements or follow-up;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuan-Sheng Zang, MD.PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Changzheng Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiao-dong Jiao, MD.PHD</last_name>
    <phone>+86-13817797639</phone>
    <email>pulava@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Changzheng Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiao-Dong Jiao, MD</last_name>
      <phone>+86-13817797639</phone>
      <email>pulava@139.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>July 28, 2017</study_first_submitted>
  <study_first_submitted_qc>August 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2017</study_first_posted>
  <last_update_submitted>November 16, 2020</last_update_submitted>
  <last_update_submitted_qc>November 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Changzheng Hospital</investigator_affiliation>
    <investigator_full_name>Baodong Qin</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Olaparib</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
    <mesh_term>Palbociclib</mesh_term>
    <mesh_term>Afatinib</mesh_term>
    <mesh_term>Vemurafenib</mesh_term>
    <mesh_term>Dabrafenib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

